ArticleCell reports2023
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Evolution and recent advances in antibody-drug conjugate therapy for lung cancer: a comprehensive systematic review based on the Trialtrove database (inception to July 1, 2025).Frontiers in oncology · 2026Pooled it
- From mechanism to clinical: research evolution and hotspot analysis of CD276/B7-H3 in cancer immunotherapy.Frontiers in immunology · 2026Pooled it
- Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026Review
- Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates.Acta pharmaceutica Sinica. B · 2026Review
- Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Current issues in molecular biology · 2026Review
- Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.Cell reports. Medicine · 2026Article
- Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.Research square · 2026Article
- A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy.International journal of molecular sciences · 2026Review
- Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers.Oncology reviews · 2026Review
- Article
- Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Molecular cancer · 2025Review
- ANTXR1 blockade enhances cardiac function in preclinical models of heart failure.Nature cardiovascular research · 2025Article
- Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging.Npj imaging · 2025Review
- Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.Biomedicines · 2025Review
- Enhanced sensitivity detection via orientational labelling of SPA-functionalized magnetic nanoparticles in lateral-flow immunoassays.Mikrochimica acta · 2025Article
- Article
- Advancements in antibody-drug conjugates as cancer therapeutics.Journal of the National Cancer Center · 2025Review
- Hypoxia-related signatures predicts survival, immunosuppression and PARP inhibitor resistance in HCC.Discover oncology · 2025Article
- m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 9 institutions in 1 country.
Yang FengTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Jaewon LeeTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Liping YangTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Mary Beth HiltonTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA; Basic Research Program, Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Karen MorrisTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA; Basic Research Program, Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Steven SeamanTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Veera V Shivaji R EdupugantiOrganic Synthesis Section, Chemical Biology Laboratory, CCR, NCI, Frederick, MD 21702, USA.
Kuo-Sheng HsuTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Christopher DowerTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Guojun YuTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Daeho SoTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Pradip BajgainTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Zhongyu ZhuProtein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, MD 21702, USA.
Dimiter S DimitrovProtein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, MD 21702, USA.
Nimit L PatelSmall Animal Imaging Program, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Christina M RobinsonAnimal Research Technical Support, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Simone DifilippantonioAnimal Research Technical Support, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Marzena DybaBiophysics Resource in the Center for Structural Biology, NCI, NIH, Frederick, MD, USA.
Amanda CorbelInvention Development Program, Technology Transfer Center, NCI, Frederick, MD 21701, USA.
Falguni BasuliChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, MD 20850, USA.
Rolf E SwensonChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, MD 20850, USA.
Joseph D KalenSmall Animal Imaging Program, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Sreedhar Reddy SutheBrickBio, Woburn, MA 01801, USA.
Myer HussainBrickBio, Woburn, MA 01801, USA.
James S ItaliaBrickBio, Woburn, MA 01801, USA.
Colby A SoudersBrickBio, Woburn, MA 01801, USA.
Ling GaoVeterans Affairs Long Beach Healthcare System, Long Beach, CA 90822, USA.
Martin J SchnermannOrganic Synthesis Section, Chemical Biology Laboratory, CCR, NCI, Frederick, MD 21702, USA.
Brad St CroixTumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA. Electronic address: stcroixb@mail.nih.gov.
National Institutes of Health · USLeidos (United States) · USScientific Systems (United States) · USGenesis Laboratories · USNational Heart Lung and Blood Institute · USProtein Express (United States) · USNational Cancer Institute · USOffice of Technology Transfer · USVA Long Beach Healthcare System · US
Funding
Targeting TEMs in Preclinical Tumor ModelsZ01BC010578 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ST CROIX, BRADLEY D · 2005 to 2008
$529kIntramural NIH HHS Z01 BC010578NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003I
Abstract
CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor-associated stroma. In previous preclinical studies, CD276 antibody-drug conjugates (ADCs) exploiting a talirine-type pyrrolobenzodiazepine (PBD) payload showed potent activity against various solid tumors but with a narrow therapeutic index and dosing regimen higher than that tolerated in clinical trials using other antibody-talirine conjugates. Here, we describe the development of a modified talirine PBD-based fully human CD276 ADC, called m276-SL-PBD, that is cross-species (human/mouse) reactive and can eradicate large 500-1,000-mm
Indexed as
ImmunoconjugatesNeoplasmsAnimalsAntibodies, Monoclonal, HumanizedB7 AntigensCell Line, TumorHumansMiceTranscription FactorsXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedB7 AntigensCD276 protein, humanImmunoconjugatesTranscription FactorsADCantibody-drug conjugateB7-H3B7H3breast cancerCD276CP: Cancerm276-SL-PBDPBDpyrrolobenzodiazepineTNBC
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.